BridgeBio Pharma heads into its June 22 earnings date with a notable split: the options market has swung back to bullish extremes, the lending pool is flush, and fresh analyst initiations are clustering above current prices — yet the stock has lost nearly 7% over the past week to close at $63.88.
The options story has reversed sharply from the defensive spike flagged in the previous note. The put/call ratio has collapsed to 0.19, well below its 20-day mean of 0.21 and near the 52-week low of 0.12. Where the prior note caught a single-day defensive spike to 0.88 — close to a three-standard-deviation event — that fear has completely unwound. Call positioning now dominates by a wide margin, suggesting options traders are leaning into the June 22 print rather than hedging against it. The lending market reinforces that picture: availability has expanded dramatically, now at 1,443% — meaning roughly fourteen shares remain available for every one currently borrowed — up from around 727% just two weeks ago. Cost to borrow is negligible at 0.46%. There is no mechanical squeeze pressure here; the borrow market is about as loose as it gets.
Short interest tells a stable, if elevated, story. Around 12.1% of the free float is short — a meaningful position, though it has barely moved over the week (+0.02%) and is only modestly higher than a month ago (+3.8%). The ORTEX short score has eased from 63.6 to 61.4 over the past ten days, a mild softening that aligns with the loosening availability. The short book looks more entrenched than active — positioned, not pressing.
The Street is leaning bullish ahead of earnings. Canaccord Genuity initiated coverage today with a Buy and a $104 target. Morgan Stanley raised its target to $98 (from $94) last week while maintaining Overweight. HC Wainwright holds firm at $110 Buy. The consensus mean target of $102.71 implies roughly 61% upside from current levels — a wide gap that reflects genuine disagreement about how fast Attruby revenue ramps and whether the encaleret launch in early 2027 can be a second growth leg. Raymond James was the lone recent dissenter, downgrading to Market Perform on May 26 without providing a new target — a notable move from a firm that had been constructive. Citi initiated at Neutral with an $82 target the week prior, adding a second cautious voice. The bull case rests on the extended patent runway for tafamidis to 2031 and a pipeline in Mendelian disorders and gene therapy delivering without further setbacks; the bear case centres on competitive pressure from injectables and near-term earnings power that remains deeply negative, with EV/EBITDA running at -95x and PE at -56x as the company invests through its commercial launch phase.
Institutional flows add an interesting wrinkle. Farallon Capital added nearly 5.9 million shares in the period ending May 22 — a substantial position build that now makes it the fourth-largest holder at 5.2% of shares. Janus Henderson added 2.2 million shares in the same window. Those are meaningful conviction moves into a name that was trading in the mid-to-high $60s at the time. On the other side, Viking Global trimmed 2.6 million shares. CEO Neil Kumar's structured plan sales — roughly 26,000 shares on May 21 for approximately $1.8 million — were already covered in the prior note; the data has not materially changed since.
The peer group offered little comfort this week. DNTH fell 8.8% on the day and SION dropped 10.8%, with most correlated names also sliding. RLAY was the sole outperformer, gaining 10.8% on the week. The broad weakness in correlated biotech names suggests macro pressure on the sector rather than company-specific selling at BBIO.
With three weeks to the June 22 print, the key variables to track are whether the Attruby revenue trajectory can be confirmed in line with the mid-2026 run-rate projections the bulls are pricing in, and whether encaleret's 2027 launch timeline holds firm.
See the live data behind this article on ORTEX.
Open BBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
